Healthcare & Fitness | Latest News & Analysis | The Australian Financial Review | AFR

New intelligent search Use sentences or keywords
The Danish drugmaker has announced the recommended pricing for its Wegovy tablet that is expected to go on sale in Australia by the end of the year.
The launch of the first weight-loss drug pills in Australia is expected to trigger an explosion in the number of people taking the drugs, but at what cost?
The first signs that an ageing parent needs help may be an empty fridge, unopened mail or a once-sociable father who no longer drives to see his friends.
He and his brother Jack said in July that they planned to sell up to 20 per cent of their holding in the pharmacy giant.
The government is upgrading offices with alarms, emergency exits and security barriers to protect staff from violent threats.
When a business achieves growth this fast, there’s usually a lot of history and experience behind it.
Shareholders are betting on the sale of Mayne’s US operations once it no longer owns an Australian manufacturing site.
Pricing indications from drugmaker Novo Nordisk suggest its weight loss pill will not be significantly cheaper than the monthly injections.
The Therapeutic Goods Administration has approved Novo Nordisk’s Wegovy pill, a move expected to dramatically increase the number of people taking GLP-1s.
Lawyers for the Melbourne public figure are arguing for his release from prison, where he is being held on domestic violence charges.
The biotech’s rough 18 months is nothing compared to what happened 20 years ago, with the chairman saying that he’ll finish in March with his head held high.
DBG Health has revealed a new name and look for 28 by Sam Wood, following domestic violence charges laid against the Melbourne fitness guru.
Andreas Fouras has slammed the proxy firms after all the medical imaging company’s pay resolutions were soundly defeated at its AGM on Wednesday.
A new targeted treatment for cancer tumours developed in Melbourne could be worth billions of dollars if human trials are successful.
CSL has pulled itself back from the brink, but there’s no room for complacency as a new leadership test arrives.
Emma Stallworthy had a plan to turn the fitness phenomenon into Peloton. It worked.
Big business and providers urge Labor to cut NDIS red tape by 25pc and ditch hourly billing, warning outdated pricing and tech threaten the $50bn scheme’s future.
The Albanese government’s flagship program to build renewables and replace coal plants has been hit by a mass exodus of new wind, solar and battery projects.
Company legend Brian McNamee is stepping aside, leaving Gordon Naylor and incoming chief Deborah Waterhouse to drive a turnaround at the blood plasma giant.
Sam Hupert said that hospitals are signing seven-year deals with his software company, defying fears that artificial intelligence will make it obsolete.
Inspired by Iain Banks novels, Melbourne founder Thomas Kelly has built Heidi into an AI health assistant used in 3 million patient consultations every week.
Although GLP-1s are a game-changer and growing in demand, Wesfarmers says Australians still have alarming rates of obesity and smoking.
Deborah Waterhouse’s appointment ends months of uncertainty for the blood plasma giant, which fell out of favour with investors after a string of earnings downgrades.
Parent company Sigma says the new GLP-1 pill will boost weight-loss drug sales, but warns that consumers are feeling the pinch.
Rebecca Donaldson’s answer during an internal town hall stunned colleagues into silence.
The Daily Habit of Successful People